Prostate Cancer News & Features
Researchers report 3 percent annual rise in intermediate- and high-risk cases
The pioneering prostate cancer drug abiraterone can significantly extend the lives of men with advanced prostate cancer if administered prior to administering chemotherapy, according to phase III clinical trial data.
New research suggests that active surveillance may be an initial approach for men with favorable intermediate-risk prostate cancer.
A recent study has determined that radiation therapy is the most common treatment for prostate cancer regardless of cancer stage, PSA level, or prognosis and risk rating.
Prostate cancer patients with detectable prostate specific antigen (PSA) following radical prostatectomy are advised to receive more aggressive radiation therapy treatment, according to a study.
Prostate Cancer Videos
- Study may support active surveillance for favorable intermediate-risk prostate cancer
- Two major studies strengthen case for prostate cancer drug before chemotherapy
- New mechanism of acquired resistance to breast cancer drugs discovered
- New opportunity to treat drug-resistant leukemia discovered
- Finding a qualified acupuncture practitioner
- Missing 30 minutes of sleep on weekdays linked to obesity, insulin resistance
- Intimate relationships as important to cancer care as medical interventions
- Lycopene may decrease risk of renal cell carcinoma in postmenopausal women
- Inherited gene variations tied to treatment-related hearing loss in cancer patients
- Improvements in cancer survival better for younger patients
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|